Tudor Investment Corp’s Forte Biosciences FBRX Stock Holding History

Tudor Investment Corp’s Portfolio FBRX Stock Details FBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-40	Closed	-$123K	–	1142
2018 Q4	$123K	Buy	+40	New	+$172K	﹤0.01%	912

Other funds holding FBRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Tudor Investment Corp's FBRX Position: Q1 2019 in Review

Tudor Investment Corp sold out of Forte Biosciences (FBRX) in Q1 2019, closing a stake of 40 shares — an estimated $123K sold.

Tudor Investment Corp first reported a position in FBRX in Q4 2018 and held it in 1 quarter. The position peaked at $123K in Q4 2018. 78 funds tracked by Wall St. Rank hold FBRX as of Q1 2019.

Tudor Investment Corp reported no remaining Forte Biosciences position as of Q1 2019 after selling out during the quarter.
Tudor Investment Corp sold 40 Forte Biosciences shares in Q1 2019, an estimated $123K.
Tudor Investment Corp first reported a position in Forte Biosciences in Q4 2018 and held it in 1 quarter.
Tudor Investment Corp's Forte Biosciences position peaked at $123K in Q4 2018.
78 funds tracked by Wall St. Rank held Forte Biosciences as of Q1 2019.

Based on Tudor Investment Corp's 13F filing for Q1 2019, filed 15 May 2019.